First human test of experimental cancer combo halted early
NCT ID NCT05904496
Summary
This early-stage study tested a new oral drug called BGB-30813, both alone and combined with the immunotherapy drug tislelizumab, in people with advanced cancers that had spread. The main goals were to find safe doses and check for early signs that the treatments might help shrink tumors. The study was terminated early and enrolled 44 participants with various solid tumors like lung, head and neck, and liver cancers.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Hackensack University Medical Center
Hackensack, New Jersey, 07601-1915, United States
-
Hospital Universitario Vall Dhebron
Barcelona, 08035, Spain
-
Jinan Central Hospital
Jinan, Shandong, 250013, China
-
Linear Clinical Research
Nedlands, Western Australia, 6009, Australia
-
Md Anderson Cancer Center
Houston, Texas, 77030-3907, United States
-
Monash Health
Clayton, Victoria, 3168, Australia
-
Next Oncology
San Antonio, Texas, 78229-6028, United States
-
Peter Maccallum Cancer Centre
Melbourne, Victoria, 3000, Australia
-
Shandong Cancer Hospital
Jinan, Shandong, 250117, China
-
Shandong Provincial Hospital
Jinan, Shandong, 250021, China
-
Start Madrid Fundacion Jimenez Diaz
Madrid, 28040, Spain
Conditions
Explore the condition pages connected to this study.